Abstract 203P
Background
The immunosuppressive tumor microenvironment (TME) appears to be the main challenge against cancer patients receiving benefits from PD-1/PD-L1-targeting immune checkpoint inhibitors (ICIs), and IL-33/ST2 signaling pathway fulfills critical roles in the TME. However, it remains uncertain whether IL-33 limits the therapeutic efficacy of anti-PD-L1 treatment.
Methods
Cellular and molecular mechanisms of the IL-33/ST2 on anti-PD-L1 treatment in lung cancer were assessed using RNA-seq, scRNA-seq, IB, and IF. A sST2-Fc fusion protein was constructed to target IL-33 and combined with an anti-PD-L1 antibody atezolizumab in lung tumor models. Based on this, bifunctional fusion proteins were generated to block IL-33 in tumors specifically targeting PD-L1. The underlying mechanisms of dual targeting of IL-33 and PD-L1 were revealed using RNA-seq, scRNA-seq, FACS, and IF.
Results
After anti-PD-L1 administration, tumor-infiltrating ST2+ regulatory T cells (Tregs) were elevated. Blocking IL-33/ST2 signaling with sST2-Fc fusion protein potentiated the antitumor efficacy of the PD-L1 antibody by boosting CD8+ T cell responses. Bifunctional fusion protein anti-PD-L1-sST2 demonstrated superior antitumor efficacy compared to combination therapy, not only inhibited tumor progression and extended survival, but also provided long-term protective antitumor immunity. Mechanistically, the superior antitumor activity of targeting both IL-33 and PD-L1 was due to a reduction in immunosuppressive factors, such as Tregs and exhausted CD8+ T cells, while increasing tumor-infiltrating cytotoxic T lymphocytes.
Conclusions
This study demonstrated that IL-33/ST2 is involved in the immunosuppression mechanism of PD-L1 antibody therapy. Blockade by sST2-Fc or anti-PD-L1-sST2 could remodel the inflammatory TME and induce a potent antitumor effect. These findings highlight the potential therapeutic strategies for tumor treatment by simultaneously targeting IL-33 and PD-L1.
Legal entity responsible for the study
Fudan University.
Funding
National Natural Science Foundation of China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract